Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Favipiravir Antiviral Gets Additional DoD Backing

by Global Biodefense Staff
August 11, 2016
Emerging Viruses and Health Security

Credit: Shutterstock

MediVector Inc. has been awarded a maximum $9,135,695 modification to previously awarded contract HDTRA1-12-C-0031 for the capability to manufacture antiviral therapeutic Favipiravir in the U.S.

The modification brings the total cumulative face value of the contract to $211,303,678 from $202,167,983.

The investigational drug candidate Favipiravir is being developed by BioDefense Therapeutics (BD Tx), a Joint Product Manager within the Medical Countermeasure Systems (JPM-MCS) Joint Project Management Office. A component of the Joint Program Executive Office for Chemical and Biological Defense, JPM-MCS aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological and nuclear threats.

Favipiravir (T-705) is a novel anti-viral compound that works against a different viral enzyme target than approved antiviral agents used to treat people who have become ill with influenza. Favipiravir inhibits the enzyme viral RNA polymerase that functions to make copies of the viral RNA segments and to synthesize mRNAs that produce the proteins that will form new viruses.

Favipiravir may be useful for the treatment of influenza infections based on its potent and selective inhibitory activities against a broad spectrum of influenza A, B, and C viruses, including strains poorly susceptible to existing drugs and its efficacy against highly pathogenic avian influenza and avian influenza virus A (H5N1) isolated from humans and birds in both in vivo and in vitro studies.

Preclinical studies indicate that favipiravir may also be effective against a variety of viruses, including flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated. Following the 2014 Ebola virus disease (EVD) outbreak in West Africa, the Department of Defense provided funding to investigate favipiravir as an EVD therapeutic.

Work under the contract has an expected completion date of March 13, 2017. The Defense Threat Reduction Agency, Fort Belvoir, Virginia, is the contracting activity.

Read also: Successful Treatment of Advanced Ebola Virus Infection with T-705 (Favipiravir) In A Small Animal Model (Antiviral Research)

Tags: AntiviralsAwardsDefense Threat Reduction AgencyEbolaInfluenza

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC